Insulin human
- Generic Name
- Insulin human
- Brand Names
- Actraphane, Actrapid, Afrezza, Entuzity, Exubera, Humulin, Humulin N, Humulin R, Insulatard, Insuman, Myxredlin, Novolin, Novolin N, Novolin R, Protaphane, Mixtard
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11061-68-0
- Unique Ingredient Identifier
- 1Y17CTI5SR
- Background
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone prod...
- Indication
Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus
- Associated Therapies
- -
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02109029
- Locations
- 🇦🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria
Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 20
- Registration Number
- NCT02028078
- Locations
- 🇦🇹
Medical University of Graz, Graz, Styria, Austria
Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 48
- Registration Number
- NCT01797601
- Locations
- 🇩🇪
University of Tuebingen, Tuebingen, Germany
Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01511159
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2011-12-29
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT01500850
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Rheinland-Pfalz, Germany
Observational Study With InnoLet® in Daily Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1030
- Registration Number
- NCT01492959
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
NovoLet® Acceptance Study Within the Hospital Practise in Indonesia
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 203
- Registration Number
- NCT01492205
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01467141
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Osnabrück, Germany
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01448070
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Glucose Control in Severely Burned Patients
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 45
- Registration Number
- NCT01307306
- Locations
- 🇨🇦
Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.